The CardiAMP therapy, developed by BioCardia, Inc., is part of the third phase of a trial that is taking place at forty medical centers across the country. The first person to undergo the therapy was treated at Johns Hopkins Hospital by a team led by Peter Johnston, principal investigator and faculty member in the Department of Medicine and Division of Cardiology at Johns Hopkins.
The Hopkins’ patient was administered a high dose of their own bone marrow cells at the point of the dysfunction in the heart. Doctors hope that the bone marrow cells will stimulate the body’s natural healing process.
If the CardiAMP therapy works, doctors can apply for approval with the Food and Drug Administration. The Maryland Stem Cell Research Fund provided funding for the project.
“Funding the clinical trial of this cell therapy, which could be the first cardiac cell therapy approved in the United States, is an important step towards treatments,” Dan Gincel, executive director of the Maryland Stem Cell Research Fund, said in a statement. “Through our clinical program, we are advancing cures and improving health care in the State of Maryland.”
According to the Centers for Disease Control and Prevention (CDC), the number one killer in the United Sates is heart disease, claiming around 610,000 victims each year.